Urinary NGAL: Use of absolute value or ratio to creatinine?

in Acta Clinica Belgica (2010), 65-3

Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) has emerged as a promising marker for the detection of acute kidney injury. This marker has been proposed for urinary measurement. However ... [more ▼]

Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) has emerged as a promising marker for the detection of acute kidney injury. This marker has been proposed for urinary measurement. However, in the literature, authors indistinctly use "absolute" value or NGAL to creatinine ratio. Up to now, there are no strong arguments favouring for one. This question is of importance as this marker is sensed to be used only on urine random samples. To find an answer to this very practical matter, one approach could be to compare biological CV(intra-individual variation) of the "absolute" and ratio results. [less ▲]

Are the complications of arteriovenous fistulas associated with an abnormal ankle-brachial index in hemodialysis patients?

in Acta Clinica Belgica (2010), 65-1

The peripheral artery disease is frequent among patients undergoing hemodialysis much more than in the general population. The ankle-brachial index (AB!) is a potent tool to screen this pathology. We ... [more ▼]

The peripheral artery disease is frequent among patients undergoing hemodialysis much more than in the general population. The ankle-brachial index (AB!) is a potent tool to screen this pathology. We analysed the relationship between ABI abnormal values and arteriovenous fistulas (AVF) complications such as stenosis and thrombosis among chronically hemodialysis pat ients (HD). [less ▲]

Urinary or plasma NGAL?: Analytical point of view

in Acta Clinica Belgica (2010)

Reference values of central blood pressure and pulse wave velocity in relations with 24 hours ambulatory blood pressure monitoring in Belgian healthy young subjects

in Acta Clinica Belgica (2010), 65(1), 66

Estimation of the Stability of Parathyroid Hormone when Stored at -80°C for a Long Period

in Clinical Journal of the American Society of Nephrology (2009), 4(12), 1988-92

L'Aliskiren : une nouvelle classe thérapeutique pour le traitement des patients hypertendus : actualités et discussion de cas cliniques en néphrologie

Conference (2009, November 17)

Avancées concernant l’Aliskiren (Rasilez®), inhibiteur direct de la rénine, et l’Aliskiren-hydrochlorothiazide (Rasilez HCT ®)

in Revue Médicale de Liège (2009), 64(11), 560-565

Aliskiren (Rasilez®), a direct renin inhibitor, is currently indicated for the treatment of essential hypertension, as monotherapy or in combination, especially with hydrochlorothiazide (Rasilez HCT®). It ... [more ▼]

Aliskiren (Rasilez®), a direct renin inhibitor, is currently indicated for the treatment of essential hypertension, as monotherapy or in combination, especially with hydrochlorothiazide (Rasilez HCT®). It may also be use to obtain a more complete blockade of the renin-angiotensin-aldosterone system (RAAS) when it is associated with an angiotensin converting enzyme inhibitor (ACEI) (or an AT1 angiotensin receptor antagonist) (ARA). There is some room for agents that may be more efficacious in reducing the progression of diabetic nephropathy than ACEI or ARA. In this context, the dual blockade of RAAS most probably offers a better efficacy than the simple blockade, but also exposes to a higher risk. Should ongoing trials confirm the preliminary favourable results, aliskiren might reach a forefront position among the armamentarium now available to optimize the RAAS blockade. The present article will summarize advances concerning the biochemical effects of the specific mode of action of aliskiren, especially the potential interferences related to increased renin/pro-renin levels, as well as results of recent clinical trials, not only in hypertension, but also in the fields of diabetes, renal insufficiency and cardiology. The objectives and design of the landmark study ALTITUDE will also be briefly presented. [less ▲]

Comparison of myocardial makers for assessing cardiovascular and all cause 3-year mortality in dialysis patients

Poster (2009, October)

L'insuffisance rénale

Conference given outside the academic context (2009)

Hypertension, prévention, traitements et conséquences

Conference (2009, September 22)